Search
Ulevostinag
go.drugbank.com/drugs/DB14721InvestigationalThis results in a CTL-mediated immune response against tumor cells and causes tumor cell lysis. [L4741] … A synthetic cyclic dinucleotide (CDN) and agonist of stimulator of interferon genes protein (STING), with potential immunoactivating and antineoplastic activities.
Synonyms: -d-arabino-adenylyl-(3'->5')-3'-deoxy-3'-fluoro-, cyclic nucleotidePF-06459988
go.drugbank.com/drugs/DB14768InvestigationalPF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Zatolmilast
go.drugbank.com/drugs/DB14790InvestigationalBPN-14770 is under investigation in clinical trial NCT02840279 (A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects).
RO-5045337
go.drugbank.com/drugs/DB14793InvestigationalRO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).
ONO-2952
go.drugbank.com/drugs/DB14802Investigationalinvestigation in clinical trial NCT01887002 (Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
PF-232798
go.drugbank.com/drugs/DB14813InvestigationalPF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Lanabecestat
go.drugbank.com/drugs/DB14814InvestigationalLanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).
Ginsenoside B2
go.drugbank.com/drugs/DB14815InvestigationalGinsenoside B2 is under investigation in clinical trial NCT00781534 (A Clinical Trial of Ginseng in Diabetes).
Tibulizumab
go.drugbank.com/drugs/DB14848InvestigationalTibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants).